Lake Street initiated coverage on Connect Biopharma with a new price target
$CNTB
Biotechnology: Pharmaceutical Preparations
Health Care
Lake Street initiated coverage of Connect Biopharma with a rating of Buy and set a new price target of $9.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/26/2026 | $6.00 | Buy | Canaccord Genuity |
| 5/21/2026 | $4.00 | Overweight | Cantor Fitzgerald |
| 12/1/2025 | $9.00 | Buy | Lake Street |
| 10/31/2025 | $10.00 | Buy | BTIG Research |
| 6/12/2025 | $7.00 | Buy | H.C. Wainwright |
| 3/4/2024 | $7.00 | Buy | H.C. Wainwright |
4 - Connect Biopharma Holdings Ltd (0001835268) (Issuer)
4 - Connect Biopharma Holdings Ltd (0001835268) (Issuer)
4 - Connect Biopharma Holdings Ltd (0001835268) (Issuer)
4 - Connect Biopharma Holdings Ltd (0001835268) (Issuer)
SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (NASDAQ:CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced that Company management will participate in a fireside chat at the H.C. Wainwright 4th Annual BioConnect Investor Conference on Tuesday, May 19, 2026 at 9:30 a.m. ET. The live webcast of the presentation may be accessed via the Investors section of the Connect website at investors.connectbiopharma.com. An archived replay of the event will be available on the website for approximately 90 days following the conference. About
– Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD continuing as planned based on independent DMC review of pre-specified interim analysis – – Expect to report topline data from both Phase 2 Seabreeze STAT studies mid-2026 – – $20.2 million private placement financing closed on March 31, 2026 – SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (NASDAQ:CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today reported financial results for the three months ended March 31, 2026, and provided a business update. "W
SAN DIEGO, April 23, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (NASDAQ:CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced that the independent Data Monitoring Committee (DMC) overseeing its Phase 2 Seabreeze STAT asthma and COPD trials evaluating rademikibart, the Company's next-generation, potentially best-in-class anti-interleukin-4-receptor alpha (IL-4Rα) antibody, has completed its review of the pre-specified interim analysis of efficacy with no recommendation for change in the sample size. "Based on the DMC's review of interim efficacy
EFFECT - Connect Biopharma Holdings Ltd (0001835268) (Filer)
F-3 - Connect Biopharma Holdings Ltd (0001835268) (Filer)
10-Q - Connect Biopharma Holdings Ltd (0001835268) (Filer)
Canaccord Genuity initiated coverage of Connect Biopharma with a rating of Buy and set a new price target of $6.00
Cantor Fitzgerald initiated coverage of Connect Biopharma with a rating of Overweight and set a new price target of $4.00
Lake Street initiated coverage of Connect Biopharma with a rating of Buy and set a new price target of $9.00
– Mr. Schoeneck is a seasoned industry executive and director with deep expertise in development and commercialization of breakthrough products and guiding companies through significant transformation and growth – SAN DIEGO, July 22, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (NASDAQ:CNTB) (Connect Biopharma, Connect, or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced the expansion of the size of its Board of Directors from six to seven directors and the appointment of Jim Schoeneck as a director effective today. "We are pleased to welcome Jim to our Board of Directors," sai
FREMONT, Calif., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Attovia Therapeutics announced the appointment of Steven Chan as Chief Financial Officer. Mr. Chan brings extensive financial strategy and operational experience and joins Attovia after serving as Chief Financial Officer at Connect Biopharma (NASDAQ:CNTB), a global clinical-stage biopharmaceutical company focused on T cell-driven therapeutics for inflammatory diseases. At Attovia, Mr. Chan will lead the company's finance and operations functions and serve on its Executive Committee, reporting to Tao Fu, Chief Executive Officer. "I am delighted to welcome Steve to Attovia at this critical growth period for the company. He brings over thirt
Announced new U.S.-based leadership with the appointment of Barry Quart, Pharm.D. as Chief Executive Officer (CEO) and David Szekeres as PresidentConnect's new management is currently evaluating the future clinical development strategy for rademikibartAs part of Connect's transformation into a U.S.-centric company, the Company will be significantly reducing its presence in ChinaCash and cash equivalents of $110.2 million expected to support planned operations into at least the first half of 2027 SAN DIEGO, CA, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (NASDAQ:CNTB) ("Connect Biopharma," "Connect" or the "Company"), a U.S.-headquartered global clinical-stage bio
SC 13D/A - Connect Biopharma Holdings Ltd (0001835268) (Subject)
SC 13D/A - Connect Biopharma Holdings Ltd (0001835268) (Subject)
SC 13D/A - Connect Biopharma Holdings Ltd (0001835268) (Subject)
– Rademikibart achieved rapid, durable efficacy results across all key endpoints through 52 weeks, with near‑maximal responses achieved in ~90% of patients – – Rademikibart was well tolerated with safety comparable to placebo – – Data presented during late-breaking oral presentation at 2026 American Academy of Dermatology Annual Meeting – – Company to host conference call and webcast today, March 30, 2026 at 8:00 a.m. ET – SAN DIEGO, March 30, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (NASDAQ:CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today anno
– Rademikibart administered as a single 300 mg 2-minute IV push to asthma and chronic obstructive pulmonary disease (COPD) patients produced rapid improvement in FEV1 with many patients experiencing improvements in airway function of ≥200 mL as early as 15 minutes post-dosing – – The rapid improvement in FEV1 demonstrated with IV rademikibart in this study provides clinical confirmation of preclinical observations that rademikibart has a unique beneficial effect on bronchodilation – – Mean FEV1 improvements of ~200 - 400 mL were maintained through Day 29 in asthma and COPD patients – – Recruitment ongoing for Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD;
The global trial met its primary endpoint showing both doses of rademikibart treatment significantly improved lung function at Week 12The significant improvement in lung function was observed as early as Week 1 and was sustained through Week 24 with both doses of rademikibartSignificant improvement in asthma control occurred early and was sustained through Week 24 for both doses of rademikibartSafety results suggest rademikibart was generally well toleratedA conference call and webcast presentation to discuss the data will be held today at 8:30 a.m. ET, details below SAN DIEGO, CA and TAICANG, China, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (NASDAQ: